126 related articles for article (PubMed ID: 8703433)
1. Recombinant outer-surface protein A (des-Cys1-OspA) from the Lyme disease spirochete Borrelia burgdorferi: high production levels in Saccharomyces cerevisiae yeast cultures.
Mendoza-Vega O; Keppi E; Bouchon B; Nguyen M; Achstetter T
Appl Microbiol Biotechnol; 1996 Jan; 44(5):624-8. PubMed ID: 8703433
[TBL] [Abstract][Full Text] [Related]
2. Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA.
Dunn JJ; Lade BN; Barbour AG
Protein Expr Purif; 1990 Nov; 1(2):159-68. PubMed ID: 2136237
[TBL] [Abstract][Full Text] [Related]
3. Structural analysis of an outer surface protein from the Lyme disease spirochete, Borrelia burgdorferi, using circular dichroism and fluorescence spectroscopy.
France LL; Kieleczawa J; Dunn JJ; Hind G; Sutherland JC
Biochim Biophys Acta; 1992 Mar; 1120(1):59-68. PubMed ID: 1554741
[TBL] [Abstract][Full Text] [Related]
4. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
5. Borrelia burgdorferi outer surface lipoproteins OspA and OspB possess B-cell mitogenic and cytokine-stimulatory properties.
Ma Y; Weis JJ
Infect Immun; 1993 Sep; 61(9):3843-53. PubMed ID: 8359905
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
[TBL] [Abstract][Full Text] [Related]
8. A murine IgG1 monoclonal antibody that binds specifically to outer surface protein A of Lyme disease spirochete Borrelia burgdorferi.
Abolhassani M; Pavia CS; Dunn JJ; Chiao JW
FEMS Microbiol Lett; 1993 May; 109(2-3):303-9. PubMed ID: 8339920
[TBL] [Abstract][Full Text] [Related]
9. Outer surface lipoproteins of Borrelia burgdorferi activate vascular endothelium in vitro.
Sellati TJ; Abrescia LD; Radolf JD; Furie MB
Infect Immun; 1996 Aug; 64(8):3180-7. PubMed ID: 8757851
[TBL] [Abstract][Full Text] [Related]
10. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
11. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
[TBL] [Abstract][Full Text] [Related]
13. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
[TBL] [Abstract][Full Text] [Related]
14. Lyme borreliosis in transgenic mice tolerant to Borrelia burgdorferi OspA or B.
Fikrig E; Tao H; Chen M; Barthold SW; Flavell RA
J Clin Invest; 1995 Oct; 96(4):1706-14. PubMed ID: 7560061
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
[TBL] [Abstract][Full Text] [Related]
16. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
Luke CJ; Carner K; Liang X; Barbour AG
J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
[TBL] [Abstract][Full Text] [Related]
17. Expression of truncated and full-length forms of the Lyme disease Borrelia outer surface protein A in Escherichia coli.
Hansson L; Noppa L; Nilsson AK; Strömqvist M; Bergström S
Protein Expr Purif; 1995 Feb; 6(1):15-24. PubMed ID: 7756835
[TBL] [Abstract][Full Text] [Related]
18. Borrelia burgdorferi outer surface protein (osp) B expression independent of ospA.
Liang FT; Caimano MJ; Radolf JD; Fikrig E
Microb Pathog; 2004 Jul; 37(1):35-40. PubMed ID: 15194158
[TBL] [Abstract][Full Text] [Related]
19. Experimental immunization against Lyme borreliosis with recombinant Osp proteins: an overview.
Sadziene A; Barbour AG
Infection; 1996; 24(2):195-202. PubMed ID: 8740122
[TBL] [Abstract][Full Text] [Related]
20. Protective immunization with plasmid DNA containing the outer surface lipoprotein A gene of Borrelia burgdorferi is independent of an eukaryotic promoter.
Simon MM; Gern L; Hauser P; Zhong W; Nielsen PJ; Kramer MD; Brenner C; Wallich R
Eur J Immunol; 1996 Dec; 26(12):2831-40. PubMed ID: 8977275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
